Veristrat® Classifier for Survival and Time to Progression in Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Erlotinib and Bevacizumab

摘要

We applied an established and commercially available serum proteomic classifier for survival after treatment with erlotinib (VeriStrat^®) in a blinded manner to pre-treatment sera obtained from recurrent advanced NSCLC patients before treatment with the combination of erlotinib plus bevacizumab. We found that VeriStrat^® could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen.